YPHA.F ASTELLAS PHARMA UNSP.ADR

Healthcare Pharmaceuticals Frankfurt Exchange
14.80 EUR
Close of Nov 12, 2026
9.94 14.80
Market cap
EUR 26.5B
P/E
12.6x
P/B
2.33x
ROE
24.4%
Dividend yield
2.94%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is YPHA.F undervalued?

Graham number
Price14.80
Graham value12.94
Premium14.3%

YPHA.F trades 14.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ASTELLAS PHARMA UNSP.ADR fundamental analysis

No fundamental analysis for ASTELLAS PHARMA UNSP.ADR yet.

ASTELLAS PHARMA UNSP.ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ASTELLAS PHARMA UNSP.ADR

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associ…

Full company profile